New program aims to help seniors master glucose monitors

NCT ID NCT05337826

Ongoing Symptom relief Sponsor: Joslin Diabetes Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests a remote education program called REST, designed to help adults aged 65 and older with insulin-treated diabetes start and keep using continuous glucose monitors (CGMs). The goal is to reduce dangerous low blood sugar episodes and improve overall glucose control. Researchers will also look at what helps or hinders CGM use in this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Continuous Glucose Monitor (device) and remote education program (REST model)
What this could lead to: If successful, this could provide a practical, patient-centered model to help older adults with diabetes use continuous glucose monitors more effectively, reducing dangerous low blood sugar episodes.
What could go wrong: This is a relatively small study (122 participants) focused on feasibility and education, not a large-scale efficacy trial. Results may not apply to all older adults, and the program may not be widely adopted outside of research settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS

Contacts and locations

Locations

Joslin Diabetes Center

Boston, Massachusetts, 02215, United States
SUNY Upstate Medical University

Syracuse, New York, 13210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.